Αποτελέσματα Αναζήτησης
10 Ιαν 2024 · The purpose of this guideline is to provide expert guidance on the systemic treatment of metastatic breast cancer (MBC) to clinicians, public health leaders, patients, and policymakers in resource-constrained settings.
- ASCO Guidelines
Using the best available evidence, ASCO expert panels...
- ASCO Guidelines
Using the best available evidence, ASCO expert panels identify and develop practice recommendations for specific areas of cancer care that would benefit from the availability of practice guidelines.
10 Ιαν 2024 · This resource-stratified guideline and related ASCO guidelines present treatment for patients with these diagnoses, when quality-assured pathology results are available to guide the selection of targeted therapy, which are not yet available in many Basic and Limited Settings.
You can also access ASCO guidelines with the tap of your finger via our app, pocket cards, and podcast: Download the free ASCO Guidelines App for iPhone/iPad or Android. Access ASCO Guideline Pocket Cards, members are eligible to receive free digital access.
This flow sheet is derived from recommendations in the 2012 Update of the Breast Cancer Follow-Up & Management Guideline in the Adjuvant Setting. This flow sheet is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician.
Only patients with HER2-positive breast cancer (overexpressed based on immunohistochemistry [ ï+] or amplified based on in situ hybridization [ratio > 2.0 or average HER2 copy number > 6.0]) should be offered adjuvant trastuzumab.
The Expert Panel strongly advocates for a multidisciplinary team management approach when considering neoadjuvant therapy for patients with breast cancer. The guideline outlines recommendations based on clinical presentation, patient characteristics, and breast cancer subtype.
